bioAffinity Technologies (BIAF) gets CyPath Lung spotlight in U.S. Medicine feature

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. filed an update describing media coverage of its CyPath® Lung diagnostic test. On September 3, 2025, the company issued a press release noting that U.S. Medicine Magazine featured CyPath® Lung in its pulmonary issue. The article highlights the test’s potential to improve lung cancer detection while lowering costs for the U.S. Department of Veterans Affairs.

The press release is included in this report as an exhibit, providing additional detail on how CyPath® Lung is being positioned in the clinical community.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

09/03/2025 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41463

46-5211056

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class	Trading Symbols	Name of each exchange on which registered
Common Stock, par value $0.007 per share	BIAF	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Warrants to purchase Common Stock	BIAFW	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 3, 2025, bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) issued a press release announcing that U.S. Medicine Magazine has featured CyPath® Lung in its pulmonary issue, highlighting the test’s potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs (VA).

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated September 3, 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 3, 2025	BIOAFFINITY TECHNOLOGIES, INC.

	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

Source: View Original Filing on SEC EDGAR

FAQ

What did bioAffinity Technologies (BIAF) disclose in this 8-K filing?

The company reported that U.S. Medicine Magazine featured its CyPath® Lung test in a pulmonary issue, emphasizing its potential to improve lung cancer detection and reduce VA costs.

What is CyPath® Lung as mentioned by bioAffinity Technologies (BIAF)?

CyPath® Lung is a diagnostic test developed by bioAffinity Technologies that, according to the disclosure, has potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs.

Why is U.S. Medicine Magazine's feature on CyPath® Lung important for bioAffinity Technologies (BIAF)?

The feature in U.S. Medicine Magazine provides visibility for CyPath® Lung within the medical community, particularly highlighting its potential benefits for lung cancer detection and VA healthcare costs.

Which exhibit is included with this bioAffinity Technologies (BIAF) 8-K?

The filing includes Exhibit 99.1, a press release issued by bioAffinity Technologies, Inc. dated September 3, 2025, and Exhibit 104, the cover page interactive data file.

Does this 8-K for bioAffinity Technologies (BIAF) report any financial results or major transactions?

No, this report is filed under Item 8.01 for Other Events and focuses on the press release about CyPath® Lung being featured in U.S. Medicine Magazine, without disclosing financial results or major transactions.

Who signed the 8-K filing for bioAffinity Technologies (BIAF)?

The filing was signed on behalf of bioAffinity Technologies, Inc. by Maria Zannes, its President and Chief Executive Officer, dated September 3, 2025.